Anti-mullerian hormone receptor type 2 transcript variants encoding different isoforms have been identified. [provided by RefSeq, Sep 2009]. Anti-mullerian hormone receptor type 2 Anti-Mullerian hormone receptor type 2 is a protein that in humans is encoded by the AMHR2 gene. This gene encodes the receptor for the anti-Mullerian hormone (AMH) which, in addition to testosterone, results in male sex differentiation. AMH and testosterone are produced in the testes by different cells and have different effects. Testosterone promotes the development of male genitalia while the binding of AMH to the encoded receptor prevents the development of the mullerian ducts into uterus and Fallopian tubes. Mutations in
Transgender hormone therapy (male-to-female) of estradiol), and not to those taking synthetic or other non-bioidentical preparations (e.g., CEEs or ethinylestradiol). Physicians also recommend broader medical monitoring, including complete blood counts; tests of renal function, liver function, and lipid and glucose metabolism; and monitoring of prolactin levels, body weight, and blood pressure. Transgender hormone therapy (male-to-female) Transgender hormone therapy of the male-to-female (MTF) type, also known as feminizing hormone therapy, is hormone therapy and sex reassignment therapy to change the secondary sexual characteristics of transgender people from masculine (or androgynous) to feminine. It is one of two types of transgender hormone therapy (the other being